FDA to Consider Easing Restrictions on Unproven Peptides Favored by RFK Jr.
The U.S. Food and Drug Administration (FDA) announced it will hold a meeting in July 2026 to consider easing restrictions on seven unapproved peptide injections, including BPC-157 and TB-500. This move aligns with pledges by Health and Human Services Secretary Robert F. Kennedy Jr., a prominent advocate for the Make America Healthy Again movement, who has personally used these substances for injury recovery. The peptides, popular among wellness influencers and celebrities for claims of muscle building and anti-aging effects, were previously barred from compounding pharmacies under the Biden administration due to significant safety risks and lack of extensive human testing. The upcoming panel of outside pharmacy advisers will review whether these substances should be moved to a category allowing routine compounding. Critics note that many of these peptides are banned by international sports authorities as doping agents and lack robust scientific validation. The decision marks a potential regulatory shift influenced by Kennedy’s skepticism of previous FDA rulings, which he characterized as illegal. This development highlights the growing tension between emerging wellness trends and established pharmaceutical safety protocols in the United States.
Wire timeline
FDA to Consider Easing Restrictions on Unproven Peptides Favored by RFK Jr.
The U.S. Food and Drug Administration (FDA) announced it will hold a meeting in July 2026 to consider easing restrictions on seven unapproved peptide injections, including BPC-157 and TB-500. This move aligns with pledges by Health and Human Services Secretary Robert F. Kennedy Jr., a prominent advocate for the Make America Healthy Again movement, who has personally used these substances for injury recovery. The peptides, popular among wellness influencers and celebrities for claims of muscle building and anti-aging effects, were previously barred from compounding pharmacies under the Biden administration due to significant safety risks and lack of extensive human testing. The upcoming panel of outside pharmacy advisers will review whether these substances should be moved to a category allowing routine compounding. Critics note that many of these peptides are banned by international sports authorities as doping agents and lack robust scientific validation. The decision marks a potential regulatory shift influenced by Kennedy’s skepticism of previous FDA rulings, which he characterized as illegal. This development highlights the growing tension between emerging wellness trends and established pharmaceutical safety protocols in the United States.
AP News